The role of pharmacogenetics in the treatment of chronic hepatitis C infection (Q38151586)

29 August 2017

The role of pharmacogenetics in the treatment of chronic hepatitis C infection (English)

1 reference

29 August 2017

1 reference

1 reference

1 reference

2

1 reference

29 August 2017

Marina Kawaguchi-Suzuki

series ordinal

1

1 reference

PubMed ID

24114761

29 August 2017

language of work or name

English

0 references

publication date

30 September 2013

1 reference

29 August 2017

1 reference

29 August 2017

34

1 reference

29 August 2017

2

1 reference

29 August 2017

185-201

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

29 August 2017

1 reference

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

21 January 2018

1 reference

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

21 January 2018

1 reference

Clinical practice. Chronic hepatitis C infection

21 January 2018

1 reference

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.

21 January 2018

1 reference

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Interferon lambdas: the next cytokine storm

21 January 2018

1 reference

Hepatitis C pharmacogenetics: state of the art in 2010.

21 January 2018

1 reference

Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy

21 January 2018

1 reference

Management and treatment of chronic hepatitis C in HIV patients

21 January 2018

1 reference

Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

21 January 2018

1 reference

Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin

21 January 2018

1 reference

IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.

21 January 2018

1 reference

The pharmacogenetic background of hepatitis C treatment

21 January 2018

1 reference

IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection

21 January 2018

1 reference

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C.

21 January 2018

1 reference

Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population

21 January 2018

1 reference

Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C.

21 January 2018

1 reference

Association between IL28B gene polymorphisms and sustained virological response in patients coinfected with HCV and HIV in Brazil

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.

21 January 2018

1 reference

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

21 January 2018

1 reference

Host genomics and HCV treatment response.

21 January 2018

1 reference

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

21 January 2018

1 reference

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

21 January 2018

1 reference

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus

21 January 2018

1 reference

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

21 January 2018

1 reference

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.

21 January 2018

1 reference

IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.

21 January 2018

1 reference

Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation.

21 January 2018

1 reference

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation

21 January 2018

1 reference

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection

21 January 2018

1 reference

Interferon lambda as a potential new therapeutic for hepatitis C.

21 January 2018

1 reference

Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation.

21 January 2018

1 reference

Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation

21 January 2018

1 reference

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

21 January 2018

1 reference

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

21 January 2018

1 reference

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

21 January 2018

1 reference

Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients

21 January 2018

1 reference

A whole-genome association study of major determinants for host control of HIV-1

21 January 2018

1 reference

IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection

21 January 2018

1 reference

Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients

21 January 2018

1 reference

Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.

21 January 2018

1 reference

Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b.

21 January 2018

1 reference

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

21 January 2018

1 reference

IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy

21 January 2018

1 reference

IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients

21 January 2018

1 reference

Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.

21 January 2018

1 reference

Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants

21 January 2018

1 reference

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin

21 January 2018

1 reference

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse

21 January 2018

1 reference

Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

21 January 2018

1 reference

Review and management of drug interactions with boceprevir and telaprevir

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

21 January 2018

1 reference

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

21 January 2018

1 reference

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

21 January 2018

1 reference

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

21 January 2018

1 reference

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

21 January 2018

1 reference

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

21 January 2018

1 reference

DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency

21 January 2018

1 reference

The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene

21 January 2018

1 reference

Functional study of the P32T ITPA variant associated with drug sensitivity in humans.

21 January 2018

1 reference

Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population

21 January 2018

1 reference

Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6.

21 January 2018

1 reference

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population

21 January 2018

1 reference

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes

21 January 2018

1 reference

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

21 January 2018

1 reference

Individual variation in inosine triphosphate accumulation in human erythrocytes

21 January 2018

1 reference

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort

21 January 2018

1 reference

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

21 January 2018

1 reference

Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis C following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype.

21 January 2018

1 reference

Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.

21 January 2018

1 reference

Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.

21 January 2018

1 reference

ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.

21 January 2018

1 reference

The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.

21 January 2018

1 reference

GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection

21 January 2018

1 reference

Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection

21 January 2018

1 reference

Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor

21 January 2018

1 reference

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

Low density lipoprotein receptor as a candidate receptor for hepatitis C virus

21 January 2018

1 reference

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

The reverse stop-signal model for CTLA4 function.

21 January 2018

1 reference

Association ofCTLA4Polymorphisms with Sustained Response to Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Infection

21 January 2018

1 reference

The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection.

21 January 2018

1 reference

Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.

21 January 2018

1 reference

STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver

21 January 2018

1 reference

Cytokines and the hepatic acute-phase response

21 January 2018

1 reference

The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis

21 January 2018

1 reference

Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics

21 January 2018

1 reference

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load

21 January 2018

1 reference

Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection

21 January 2018

1 reference

Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection

21 January 2018

1 reference

Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis

21 January 2018

1 reference

Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.

21 January 2018

1 reference

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy

21 January 2018

1 reference

Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.

21 January 2018

1 reference

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

21 January 2018

1 reference

Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy

21 January 2018

1 reference

NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1349

1 reference

release_tz7byrc7p5h3vbbq7ui7vs4qa4

29 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tz7byrc7p5h3vbbq7ui7vs4qa4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

24114761

1 reference

PubMed ID

24114761